89 related articles for article (PubMed ID: 6119282)
1. Route of administration as a factor in the selectivity of hormone suppression of a somatostatin analog in rats.
Lien EL; Garsky VM
Horm Metab Res; 1981 Dec; 13(12):675-8. PubMed ID: 6119282
[TBL] [Abstract][Full Text] [Related]
2. D-Trp8-D-Cys14-somatostatin--demonstration of its differential suppressive activity in juvenile diabetics.
Neuhaus C; Kerner W; Maier V; Pfeiffer EF
Horm Metab Res Suppl; 1979; (8):115-8. PubMed ID: 395066
[TBL] [Abstract][Full Text] [Related]
3. Development of specific and non-specific somatostatin analogs.
Nakano T; Harano Y; Emura J; Kimura T; Sakakibara S; Shigeta Y
Horm Metab Res; 1986 Feb; 18(2):98-102. PubMed ID: 2870971
[TBL] [Abstract][Full Text] [Related]
4. Prolonged suppression of insulin release by a somatostatin analog.
Lien EL; Garsky VM
Endocrinology; 1978 Jul; 103(1):81-5. PubMed ID: 744088
[TBL] [Abstract][Full Text] [Related]
5. Influence of continuous physiologic hyperinsulinemia on glucose kinetics and counterregulatory hormones in normal and diabetic humans.
Saccà L; Sherwin R; Hendler R; Felig P
J Clin Invest; 1979 May; 63(5):849-57. PubMed ID: 447832
[TBL] [Abstract][Full Text] [Related]
6. Non-selective inhibition of basal glucagon release by [D-Cys14]-analogues of somatostatin in the rat.
Märki F; Kamber B; Rink H; Sieber P
J Endocrinol; 1979 Jun; 81(3):315-23. PubMed ID: 469462
[TBL] [Abstract][Full Text] [Related]
7. Effects of somatostatin analogs on glucose homeostasis in rats.
Schmid HA; Brueggen J
J Endocrinol; 2012 Jan; 212(1):49-60. PubMed ID: 21987782
[TBL] [Abstract][Full Text] [Related]
8. Effect of twice daily subcutaneous administration of a long-acting somatostatin analog on 24-hour plasma glucose profiles in patients with insulin-dependent diabetes mellitus.
Dimitriadis G; Gerich J
Horm Metab Res; 1985 Oct; 17(10):510-1. PubMed ID: 2866155
[TBL] [Abstract][Full Text] [Related]
9. Effect of a long acting glucagon selective somatostatin analogue on plasma glucose, insulin and glucagon levels in the anaesthetized rat during arginine infusion.
Lien E; Sarantakis D
Diabetologia; 1979 Jul; 17(1):59-64. PubMed ID: 467854
[TBL] [Abstract][Full Text] [Related]
10. Role of glucagon, catecholamines, and growth hormone in human glucose counterregulation. Effects of somatostatin and combined alpha- and beta-adrenergic blockade on plasma glucose recovery and glucose flux rates after insulin-induced hypoglycemia.
Rizza RA; Cryer PE; Gerich JE
J Clin Invest; 1979 Jul; 64(1):62-71. PubMed ID: 36413
[TBL] [Abstract][Full Text] [Related]
11. Effect of a 12-hour subcutaneous infusion of somatostatin-14 on blood glucose, insulin and glucagon levels in healthy subjects and insulin dependent diabetics.
Villaume C; Beck B; Kolopp M; Toussain P; Debry G
Biomed Pharmacother; 1986; 40(2):61-4. PubMed ID: 2875745
[TBL] [Abstract][Full Text] [Related]
12. Dissociated effects of somatostatin analogs on arginine-induced insulin, glucagon and growth hormone release in acromegalic patients.
Wajchenberg BL; Cesar FP; Leme CE; Borghi VC; Souza VC; Souza IT; Neto DG; Germek OA; Coy DH; Comaru-Schally AM
Horm Metab Res; 1983 Oct; 15(10):471-4. PubMed ID: 6139329
[TBL] [Abstract][Full Text] [Related]
13. The pancreatic glucagon and C-peptide secretion during hyperinsulinemia in euglycemic glucose clamp with or without somatostatin infusion in normal man.
Wu MS; Ho LT
Horm Metab Res; 1987 Jun; 19(6):253-6. PubMed ID: 2887501
[TBL] [Abstract][Full Text] [Related]
14. Central effects of thyronamines on glucose metabolism in rats.
Klieverik LP; Foppen E; Ackermans MT; Serlie MJ; Sauerwein HP; Scanlan TS; Grandy DK; Fliers E; Kalsbeek A
J Endocrinol; 2009 Jun; 201(3):377-86. PubMed ID: 19273499
[TBL] [Abstract][Full Text] [Related]
15. Effect of somatostatin in the Syrian hamster bearing a transplantable islet-cell tumor.
Luyckx AS; Lefebvre PJ
Horm Metab Res; 1978 Mar; 10(2):105-10. PubMed ID: 206496
[TBL] [Abstract][Full Text] [Related]
16. Superactive somatostatin analog decreases plasma glucose and glucagon levels in diabetic rats.
Karashima T; Schally AV
Peptides; 1988; 9(3):561-5. PubMed ID: 2901737
[TBL] [Abstract][Full Text] [Related]
17. Antidiabetic action of somatostatin after oral glucose loading: due to suppression of glucagon and growth hormone or of intestinal carbohydrate absorption?
Bratusch-Marrain P; Vierhapper H; Grubeck-Loebenstein B; Waldhäusl W; Nowotny P
Horm Metab Res; 1981 Jun; 13(6):305-9. PubMed ID: 6114914
[TBL] [Abstract][Full Text] [Related]
18. Increased responses of glucagon and glucose production to hypoglycemia with intraperitoneal versus subcutaneous insulin treatment.
Wan CK; Giacca A; Matsuhisa M; El-Bahrani B; Lam L; Rodgers C; Shi ZQ
Metabolism; 2000 Aug; 49(8):984-9. PubMed ID: 10954014
[TBL] [Abstract][Full Text] [Related]
19. Importance of hyperglucagonemia in eliciting the sepsis-induced increase in glucose production.
Lang CH; Bagby GJ; Blakesley HL; Spitzer JJ
Circ Shock; 1989 Nov; 29(3):181-91. PubMed ID: 2574079
[TBL] [Abstract][Full Text] [Related]
20. Response of plasma somatostatin-like immunoreactivity to the administration of alloxan in dogs.
Schusdziarra V; Harris V; Unger R
Horm Metab Res; 1979 Aug; 11(8):457-9. PubMed ID: 499995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
